Pyrrolidine Amide Glucocorticoid Receptor Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic glucocorticoid treatment for inflammatory diseases is hindered by adverse effects such as insulin resistance, diabetes, hypertension, glaucoma, depression, osteoporosis, and adrenal suppression, with existing partial agonists and selective glucocorticoid receptor modulators not yet approved for clinical use.
Innovation Solution
Development of novel compounds according to general formula (I), which act as potent modulators of the glucocorticoid receptor, selectively favoring transrepression over transactivation to minimize adverse effects while maintaining therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoids are used to treat inflammatory diseases, then anti-inflammatory and immunosuppressive effects are achieved, but severe adverse effects occur including insulin resistance, diabetes, hypertension, glaucoma, depression, osteoporosis, and adrenal suppression
Solution Approach 1:
The patent segments the glucocorticoid receptor's functional pathways into transactivation and transrepression mechanisms. By designing compounds that selectively modulate these separate pathways, the invention achieves anti-inflammatory effects through transrepression while minimizing adverse effects associated with transactivation, thus resolving the contradiction between therapeutic efficacy and harmful effects
Solution Approach 2:
The invention applies local quality by creating glucocorticoid receptor modulators with differential activity at different receptor conformations or cellular locations. The compounds exhibit preferential binding to specific GR conformations that favor transrepression over transactivation, thereby producing localized therapeutic effects while avoiding systemic adverse effects
2Ease of operation
If glucocorticoids are discontinued abruptly after chronic treatment, then treatment can be stopped, but severe withdrawal symptoms occur
Solution Approach 1:
The patent employs dynamics by developing compounds with adjustable dosing regimens and varying potencies. The modular chemical structures allow for fine-tuning of pharmacokinetic properties, enabling gradual dose adjustments that minimize withdrawal symptoms while maintaining flexibility in treatment discontinuation protocols
3Object-affected harmful factors
If partial agonists or selective glucocorticoid receptor modulators are developed to reduce adverse effects, then transactivation pathways are avoided, but these compounds have not yet been approved for clinical use
Solution Approach 1:
The invention applies parameter changes by systematically varying chemical parameters in the pyrrolidine amide structure (substituents at different positions, stereochemistry, molecular weight, lipophilicity) to optimize the balance between anti-inflammatory potency and selectivity for transrepression pathways, thereby improving the risk-benefit profile for clinical approval
Data Source
AI summary
The invention relates to compounds according to general formula (I),which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.